Artelo Biosciences ARTL
NASDAQ ARTL
$2.18 +0.02 (+0.93%)
At close: Nov 11, 2026 · 4:00 PM EST

Artelo Biosciences (ARTL) Net Income Attributable to Noncontrolling Interests (2023)

Updated

Analysis

Artelo Biosciences (ARTL) Net Income Attributable to Noncontrolling Interests (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Artelo Biosciences 49.32 Mn 32.53 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 4,000.00
Mar 31, 2023 49,000.00
API Access

Artelo Biosciences Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=ARTL&period=max&api_key=YOUR_API_KEY